CRISPR crops—exempt from GMO regulations—reaching US market in record time

| | January 15, 2018
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

CRISPR–Cas9-edited plants can be cultivated and sold free from regulation, the US Department of Agriculture (USDA) is making increasingly clear. The agency gave a free pass to Camelina sativa, or false flax, with enhanced omega-3 oil. And more recently, in October, said that a drought-tolerant soybean variety developed with CRISPR falls outside of its regulatory purview. This laissez-faire attitude from the agency shaves years and tens of millions of dollars off the cost of bringing a biotech plant to market.

It would have taken Yield10 at least six years and $30–50 million to test and collect the data necessary to bring genetically engineered camelina through the full USDA regulatory process, says Peoples. “We did this in two years and [USDA’s decision] took two months, and I assure you we didn’t spend $30 million on it,” he says. The company will present its technology to the US Food and Drug Administration’s voluntary review process, he says.

The edited camelina and the drought-tolerant soybean developed by scientists at USDA’s research arm are two of at least five CRISPR–Cas9-edited organisms to sidestep USDA’s regulatory system in the last two years.

Screen Shot at AM

Read full, original post: With a free pass, CRISPR-edited plants reach market in record time

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend